Fentanyl crackdown expands DEA power to classify drugs by chemical structure alone

What it does

This bill amends the Controlled Substances Act to automatically classify all fentanyl-related substances (any chemical structurally similar to fentanyl) as Schedule I controlled substances, and streamlines the registration process for researchers studying fentanyl and other Schedule I drugs. It allows researchers with existing Schedule I/II registrations to begin fentanyl research within 30 days of notifying the DEA, and permits small-scale manufacturing of controlled substances for research purposes without a separate manufacturing license.

Why we flagged it

The bill's primary mechanism is a broad, structural-similarity-based scheduling authority for fentanyl analogues—a significant expansion of DEA power. The secondary mechanism streamlines research registration, reducing friction for legitimate fentanyl research. Both are enforcement/regulatory in nature, not a tax or subsidy.

What the text implies

• The structural-similarity definition for fentanyl-related substances is extremely broad and may capture legitimate pharmaceutical compounds or research chemicals not intended as drugs, creating potential for over-criminalization of chemists and researchers.
• The bill grants the Attorney General power to classify substances as Schedule I based solely on structural similarity, with no explicit requirement for evidence of abuse potential, human toxicity, or illicit use—a departure from traditional scheduling criteria.
• Researchers can now conduct fentanyl research with minimal DEA oversight: 30-day notification for existing registrants, 45-day approval for new ones, and no new inspection required when adding a second substance in the same schedule, reducing diversion controls.
• The bill allows small-scale manufacturing of controlled substances (including fentanyl derivatives) for research without a manufacturing license, provided it is disclosed in a research protocol—a significant relaxation of manufacturing controls.
• The 'rule of construction' retroactively endorses the McCray court interpretation, potentially exposing individuals prosecuted before this bill's enactment to collateral challenges or appeals based on the new statutory definition.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill addresses a genuine public-health crisis by closing a legal loophole that allowed illicit fentanyl analogues to evade prosecution, potentially saving lives. However, it grants the DEA broad, largely unreviewable power to classify new chemicals as Schedule I based on structural similarity alone, with minimal procedural safeguards, and streamlines research registration in ways that reduce oversight of controlled-substance handling.

Named in the bill

Drug Enforcement Administration (DEA), Attorney General, Department of Health and Human Services, Department of Defense, Department of Veterans Affairs, Controlled Substances Act, Federal Food, Drug, and Cosmetic Act

Where it stands

31 cosponsors: 24 Republicans, 6 Democrats, 1 Independents.

• Jan 30, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Jan 30, 2025 — Referred to Senate Committee on the Judiciary · Congress.gov: “Read twice and referred to the Committee on the Judiciary”
• Feb 27, 2025 — Reported out of committee · Congress.gov: “Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably”
• Mar 14, 2025 — Passed the Senate · Congress.gov: “Passed Senate with an amendment by Yea-Nay Vote. 84 - 16. Record Vote Number: 127”
• Jun 12, 2025 — Passed both chambers · Congress.gov: “On passage Passed by the Yeas and Nays: 321 - 104 (Roll no. 166). (text: 6/11/2025 CR H2625-2627)”
• Jul 8, 2025 — Sent to president · Congress.gov: “Presented to President”
• Jul 16, 2025 — Signed into law · Congress.gov: “Became Public Law No: 119-26”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

5 lobbying clients named this bill on 5 disclosure filings across 3 quarters, Dec 2025 to Jun 2026. Those filings disclosed $165,000 in lobbying spend. A filing names 7 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 78% of bills with at least one filing.

Bill Cassidy, the sponsor, reported $1,329,254 in PAC receipts in the 2026 cycle.

• Peace Officers Research Association of California — $50,000 on 1 filing
• University of Iowa — $50,000 on 1 filing
• Brainfutures — $40,000 on 1 filing
• Due Process Institute — $15,000 on 1 filing
• Act for America — $10,000 on 1 filing

Lobbying Disclosure Act filings through Jul 17, 2026. A filing shows who paid to lobby on a bill it names, not what changed.